The Phase 3 POETYK PsA-1 trial data announced by the company reflects that patients treated with Sotyktu achieved ACR20 response and demonstrated “at least a 20 per cent improvement in signs and symptoms of disease compared with placebo at Week 16". Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/bristol-myers-squibbs-sotyktu-shows-promising-efficacy-in-psoriatic-arthritis-treatment/121797340